Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Switzerland that focuses on the discovery and development of small-molecule drugs for neurological disorders. The company specializes in allosteric modulators, which are orally available compounds designed to fine-tune receptor activity in the brain. Its business model relies on advancing proprietary drug candidates and partnering with larger pharmaceutical companies for clinical development.
Financial Statements
In thousands, USD
FY 2025
FY 2024
FY 2023
FY 2022
Total Revenues
173
410
1,617
1,445
Gross Profit
173
410
1,617
1,445
Selling, General & Administrative Expenses
2,316
2,311
2,673
3,742
Research & Development Expenses
672
854
1,187
8,244
Operating Profit
(2,815)
(2,755)
(2,243)
(10,541)
Interest and Investment Income
—
27
64
29
Interest Expense
(16)
(4)
(321)
(292)
Non-Operating Income
(4,012)
(2,177)
—
—
Total Non-Operating Income
(4,028)
(2,154)
(257)
(263)
Income Before Provision for Income Taxes
(6,843)
(4,909)
(2,500)
(10,804)
Consolidated Net Income
(6,843)
(4,909)
(2,500)
(10,804)
Net Income Attributable to Discontinued Operations
114
11,965
(8,056)
(10,000)
Net Income Attributable to Common Shareholders
(6,728)
7,056
(10,556)
(20,804)
Basic EPS
-7.20
8.40
-16.80
-55.20
Diluted EPS
-7.20
8.40
-16.80
-55.20
Basic Weighted Average Shares Outstanding
895
818
619
377
Diluted Weighted Average Shares Outstanding
895
818
619
685
Shares Outstanding
1,232
1,069
1,043
497
FY 2025
FY 2024
FY 2023
FY 2022
Cash and Cash Equivalents
1,639
3,342
3,865
6,957
Short-Term Investments
5
6
1
3
Total Cash and Cash Equivalents
1,644
3,348
3,866
6,960
Accounts Receivable
20
16
110
417
Other Receivables
—
—
41
181
Total Trade Receivables
20
16
151
598
Other Current Assets
16
178
217
270
Total Current Assets
1,680
3,541
4,235
7,829
Net Property, Plant & Equipment
34
43
353
399
Long-Term Investments
4,141
7,094
54
54
Other Long-Term Assets
509
—
—
—
Total Assets
6,364
10,678
4,642
8,282
Accounts Payable
1,191
795
2,384
2,996
Current Portion of Leases
8
7
274
286
Unearned Revenue
—
—
235
—
Total Current Liabilities
1,199
802
2,893
3,282
Leases
27
35
70
87
Other Long-Term Liabilities
372
164
533
—
Total Long-Term Liabilities
399
199
603
87
Total Liabilities
1,598
1,001
3,496
3,369
Common Stock
2,187
1,844
1,844
1,153
Treasury Stock
(1,015)
(870)
(910)
(6,279)
Additional Paid-in Capital
331,928
331,003
330,815
334,132
Accumulated Other Comprehensive Income
31,757
31,063
29,815
25,768
Retained Earnings
(360,091)
(353,362)
(360,418)
(349,862)
Total Common Shareholders' Equity
4,767
9,677
1,145
4,913
Total Shareholders' Equity
4,767
9,677
1,145
4,913
Total Liabilities and Shareholders' Equity
6,364
10,678
4,642
8,282
FY 2025
FY 2024
FY 2023
FY 2022
Net Income
(6,728)
7,056
(10,556)
(20,804)
Depreciation & Amortization
8
260
306
637
Share-Based Compensation Expense
71
503
1,794
6,686
Other Adjustments
3,928
(11,964)
250
211
Changes in Trade Receivables
(5)
93
307
(247)
Changes in Accounts Payable
391
(1,146)
(613)
(476)
Changes in Unearned Revenue
—
(38)
324
—
Changes in Other Operating Activities
163
(137)
196
(9,127)
Cash from Operating Activities
(2,171)
(5,374)
(7,992)
(16,437)
Capital Expenditure
—
(1)
(7)
(1)
Purchases of Investments
(795)
—
—
—
Proceeds from Sale of Investments
—
—
—
4
Proceeds from Business Divestments
114
5,120
—
—
Other Investing Activities
—
(473)
—
—
Cash from Investing Activities
(681)
4,645
(7)
3
Issuance of Common Shares
1,229
241
5,769
4,542
Net Issuance / (Repurchases) of Common Shares
1,229
241
5,769
4,542
Other Financing Activities
(45)
(136)
(504)
(1,737)
Cash from Financing Activities
1,184
105
5,265
3,103
Effect of Exchange Rate Changes on Cash and Cash Equivalents
(35)
100
(357)
(196)
Increase / (Decrease) in Cash, Cash Equivalents and Restricted Cash